Abstract:Today the problem of treatment of patients with benign prostatic hyperplasia (BPH) is the actual one. BPH is an age-related chronic progressive disease. It is especially relevant for men over the age of 50 years. According to WHO demographic data, the world’s population is becoming older, so the incidence of BPH is going to increase, that leads to a significant decline in quality of life due to dysfunction of the lower urinary tract and the presence of lower urinary tract symptoms (LUTS). The management of BPH has evolved from surgery to conservative therapy. The use of 5α- reductase inhibitors, which affects the pathogenetic links of the disease, reduces the concentration of dihydrotestosterone and induces the apoptosis of epithelial cells of the prostate, is pathogenetically justified in the treatment of BPH. The objective: to study the effectiveness of treatment of BPH with dutasteride, which belongs to the group of 5α-reductase inhibitors. Materials and methods. 58 patients with BPH 52-75 years old were examined. The persons were divided into two groups. The patients in the first group received dutasteride for 6 months, the second group – for 12 months. All patients were examined ambulatory by the laboratory and instrumental diagnostic methods: an assessment of complaints by the International Prostate Symptom Score (IPSS), an assessment of the quality of life by the QoL scale, digital rectal and ultrasound examinations, bladder ultrasound examination, uroflowmetry, prostate-specific antigen level, general blood and urinary tests, determination of creatinine and urea. Uroflowmetry assessed the rate of urodynamics, identified and determined the degree of urinary disorders . Results. A positive effect of dutasteride treatment was observed in patients of both groups, but the best results were in the second group. The regression of LUTS, decreased pancreatic volume and residual urine output were in the patients. Conclusions. The results of the research demonstrated that dutasteride is an effective agent in the treatment of benign prostatic hyperplasia (BPH), which acts on the mechanism of hyperplasia. The drug is well tolerated by patients. The effect of dutasteride treatment is achieved through its continuous and long-term use. The timely diagnosis of BPH and its treatment will allow to stop the pathological process and return the man to a normal quality of life.

"Current and Emerging Therapies for Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia"

Pathophysiology of benign prostate enlargement and lower urinary tract symptoms: Current concepts

Six Novel Minimally Invasive Therapies for Benign Prostatic Hyperplasia

Overview of current pharmacotherapeutic options in benign prostatic hyperplasia

Epidemiology and risk factors of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction

Minimally invasive interventions for lower urinary tract symptoms: What sits between medical therapy and transurethral resection of the prostate

Emerging drugs for the treatment of benign prostatic hyperplasia: a 2023 update

Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors

Mitigating Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Ameliorating Sexual Function and Psychological Well-Being in Older Men

Recent Advancements in Prostate Catheters and Stents for Management of Benign Prostatic Hyperplasia

Pharmacological Approaches in Managing Symptomatic Relief of Benign Prostatic Hyperplasia: A Comprehensive Review

Diet as a risk factor and intervention for lower urinary tract symptoms secondary to benign prostatic hyperplasia

Evolving Role of Silodosin for the Treatment of Urological Disorders – A Narrative Review

Dustarin in the Treatment of Patients with Benign Prostatic Hyperplasia

The Role of Inflammation in Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH) and Its Potential Impact on Medical Therapy

Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects

Role of Phytotherapy in the Management of BPH: A Summary of the Literature

Medical Advancements in Benign Prostatic Hyperplasia Treatments

Incidence and Prevalence of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Primary Care—The Triumph Project

Summary Paper on the 2023 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms

Ejaculation sparing of classic and minimally invasive surgical treatments of LUTS/BPH